Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Precision BioSciences, Inc.

< Previous 1 2 3 4 Next >
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Second Quarter Results on August 4, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Change to its Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.